1. Home
  2. PROF vs KROS Comparison

PROF vs KROS Comparison

Compare PROF & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Profound Medical Corp.

PROF

Profound Medical Corp.

N/A

Current Price

$7.44

Market Cap

248.8M

Sector

Health Care

ML Signal

N/A

Logo Keros Therapeutics Inc.

KROS

Keros Therapeutics Inc.

N/A

Current Price

$10.38

Market Cap

222.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PROF
KROS
Founded
N/A
2015
Country
Canada
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
248.8M
222.7M
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
PROF
KROS
Price
$7.44
$10.38
Analyst Decision
Strong Buy
Buy
Analyst Count
5
7
Target Price
$11.14
★ $19.83
AVG Volume (30 Days)
★ 184.5K
168.9K
Earning Date
11-05-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
25.89
★ 146.00
EPS
★ N/A
N/A
Revenue
$16,098,000.00
★ $243,864,000.00
Revenue This Year
$61.76
N/A
Revenue Next Year
$70.98
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
★ 50.73
N/A
52 Week Low
$4.91
$8.98
52 Week High
$8.95
$22.55

Technical Indicators

Market Signals
Indicator
PROF
KROS
Relative Strength Index (RSI) 62.40 45.34
Support Level $6.38 N/A
Resistance Level $7.92 $11.86
Average True Range (ATR) 0.50 0.70
MACD 0.13 -0.08
Stochastic Oscillator 75.61 43.10

Price Performance

Historical Comparison
PROF
KROS

About PROF Profound Medical Corp.

Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.

About KROS Keros Therapeutics Inc.

Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Share on Social Networks: